New perspectives on the use of niacin in the treatment of lipid disorders.
about
Niacin for primary and secondary prevention of cardiovascular eventsNiacin, an old drug with a new twistOptimal lipid modification: the rationale for combination therapyDescription of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of actionThe nuances of atherogenic dyslipidemia in diabetes: focus on triglycerides and current management strategies.A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention.Utilization patterns of extended-release niacin in Canada: analysis of an administrative claims database.Niacin: another look at an underutilized lipid-lowering medication.Low high-density lipoprotein cholesterol: current status and future strategies for management.Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation.The flavonoid luteolin inhibits niacin-induced flushA quercetin containing supplement reduces niacin-induced flush in humans.Niacin for primary and secondary prevention of cardiovascular events.Management of dyslipidemia in women in the post-hormone therapy era.Extended release niacin-laropiprant in patients with hypercholesterolemia or mixed dyslipidemias improves clinical parametersExtended-release niacin/lovastatin: the first combination product for dyslipidemia.The association of lipoprotein lipase PvuII polymorphism and niacin intake in the prevalence of metabolic syndrome: a KMSRI-Seoul studyEpidemiology, pathophysiology and therapeutic implications of lipoprotein(a) in kidney disease.Recent advances in the secondary prevention of coronary heart disease.Considerations in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation.Present-day uses of niacin: effects on lipid and non-lipid parameters.Metabolic syndrome management.Recommendations for management of dyslipidemia in high cardiovascular risk patients.The role of lipids in the pathogenesis and treatment of type 2 diabetes and associated co-morbidities.The efficacy of vitamin C supplementation on reducing total serum cholesterol in human subjects: a review and analysis of 51 experimental trials.Fixed-dose combination of extended-release niacin plus simvastatin for lipid disorders.Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular risk.Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia.Lipoic acid improves hypertriglyceridemia by stimulating triacylglycerol clearance and downregulating liver triacylglycerol secretion.Randomized, double-blind, placebo-controlled and active-controlled study to assess the relative abuse potential of oxycodone HCl-niacin tablets compared with oxycodone alone in nondependent, recreational opioid users.Safety considerations and potential interactions of vitamins: should vitamins be considered drugs?Independent and combined effects of aerobic exercise and pharmacological strategies on serum triglyceride concentrations: a qualitative review.Pharmacological measures to increase HDL-C among high risk isolated low HDL cases: a randomized study amongst north Indians.Niacin's role in the statin era.New evidence for nicotinic acid treatment to reduce atherosclerosis.Important considerations for treatment with dietary supplement versus prescription niacin products.Effect of niacin on endothelial function: a systematic review and meta-analysis of randomized controlled trials.Acetylsalicylic acid reduces niacin extended-release-induced flushing in patients with dyslipidemia.α-Lipoic acid as a triglyceride-lowering nutraceutical.Pleiotropic effects of niacin: Current possibilities for its clinical use.
P2860
Q24203613-8C598BFD-9738-46BD-81FD-DBDC304A98E5Q27002774-040547F8-40AC-4C69-8DD2-DCD8AB361C90Q28219266-C2F4A275-607A-4AA4-927B-22A21E2DACABQ28285064-748EECA4-B8D4-4AEE-B73F-52A0712A1D0DQ30357715-6ABC3A12-44B5-47FA-81B1-FC417AF006BEQ33765072-1465B6CF-004B-4A5E-AD69-8C4D28368FCEQ34179056-14A1AFEC-E1A5-4239-BD09-D8BE8AB95AC6Q34255686-B88A5F7F-D5E7-4A59-99F4-9CFCF4D418ECQ34334846-221DDFC4-7036-44C9-841A-60722B311573Q34435166-61093438-FC2B-4697-BBCA-E027D174ADC9Q34587640-AF326233-3379-4657-9AF0-A6EB2E35D14CQ34597886-13A4C1A1-378E-454F-9D22-F8CD20624D40Q34682221-1D489621-4D3F-4A96-A8B6-6B4E9743F215Q34722828-887A5011-A656-4264-889D-221BD2AA8B36Q35440499-ADC44070-8DE5-4126-B98A-9F2DF1AD3723Q35821875-FCA21B4B-D9DF-4A3A-97D1-77A8EA08D4E3Q35863314-64B4B8D6-DEC2-41E4-93A8-4508D5FADBACQ35879090-4F276DC9-2935-4417-ADE1-19BB29F21520Q35925701-F39EA7A4-6E39-4E8F-B56C-7453AA6C9412Q36288839-A5EB838E-71E4-432C-9FD1-D47A4A6CA8D3Q36904907-3CE0D314-47DF-4B94-993D-2B35679C6F22Q36916909-D845C153-732F-4D6C-85DE-6A2C1327F3DDQ36981307-82B1D35E-EEA0-47DA-A100-7F9F13429D40Q37024780-3984A3F3-3986-4AF7-880B-2D38E91CFB97Q37107865-9C6A1A5C-96EC-4D4E-8CAD-D390E6548923Q37329136-B0DDA99A-A4A7-4E36-99BD-0D36B337916BQ37367666-86DD7C8B-373B-4392-A634-5DD47192D560Q37376937-C80C629F-EC40-46A8-BEC9-7679F01C9515Q37407275-B96B9DE6-3073-4A13-9CEE-A019614EB3D1Q37457193-3FAB3CF7-2674-45B9-A9FD-C427B3046F91Q37664340-348A6073-F3BE-4602-8327-7165C157887FQ37667487-B725509B-4E94-49F6-A7CB-AABF9D3BA31AQ37690828-FD972FD8-0B77-4FA1-AA67-9F498CB3DD60Q37766890-1942340F-2BD7-4089-95DE-A37DD3C1C27EQ37799365-C3ECD2E3-10F2-40DD-87C5-D9AF08619EE2Q37862929-08A6C2F7-AA9C-432B-81A6-95E23AA0A672Q38175934-43DD89D1-421A-4C2E-858E-75A1995E47CAQ38382780-BF135BDF-AF6C-44E2-831E-BF81BEC930B1Q38559352-FC6D517A-7DF6-4140-8A21-D1E4C9844E56Q38810790-D6509CD4-AFED-44C4-B10B-330F78062D41
P2860
New perspectives on the use of niacin in the treatment of lipid disorders.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
New perspectives on the use of niacin in the treatment of lipid disorders.
@ast
New perspectives on the use of niacin in the treatment of lipid disorders.
@en
type
label
New perspectives on the use of niacin in the treatment of lipid disorders.
@ast
New perspectives on the use of niacin in the treatment of lipid disorders.
@en
prefLabel
New perspectives on the use of niacin in the treatment of lipid disorders.
@ast
New perspectives on the use of niacin in the treatment of lipid disorders.
@en
P1476
New perspectives on the use of niacin in the treatment of lipid disorders.
@en
P2093
James McKenney
P304
P356
10.1001/ARCHINTE.164.7.697
P407
P577
2004-04-01T00:00:00Z